Calls for papers
-
The Portuguese Health Authority (Infarmed) has approved Sandoz’s AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to developer Vectura. Sandoz licensed AirFluSal Forspiro from Vectura in… Read more . . .
-
Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said… Read more . . .
-
California-based CDMO Formex has announced the hires of two new scientists, Ke Shi and Wade Pathak, as well as the acquisition of new spray drying and capsule filling equipment. Formex Senior Director of Business Development… Read more . . .
-
Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug… Read more . . .
-
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis… Read more . . .
-
Retrophin has announced that Stephen Aselage will take over as interim CEO immediately, replacing company founder and CEO Martin Shkreli. According to reports, Shkreli was fired for “stock trading irregularities” and other rules violations. Aselage… Read more . . .
-
Twenty-five years after its first meeting in a Glaxo Group Research lecture theater, the Aerosol Society’s annual Drug Delivery to the Lungs conference marks its silver anniversary with DDL 25, taking place December 10-12 at… Read more . . .
-
Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said,… Read more . . .
-
According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company’s naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for… Read more . . .
-
Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK